four-oaks-partners

SAB

Leading Research & Development Executives


Jay Birnbaum

Jay Birnbaum

Dr. Birnbaum is a pharmacologist and consultant to pharmaceutical companies. His experience includes Novartis/Sandoz Pharmaceuticals and Kythera Biopharmaceuticals in addition to serving on scientific advisory boards of several companies. Dr. Birnbaum has an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.


Trevor J. Hallam

Trevor J. Hallam

Dr. Hallam has 25 years of drug discovery and development experience. His background includes Smith Kline, Glaxo, Roche, Rhone Poulenc Rorer, AstraZeneca and his current position as CSO at Sutro BioPharma. Dr. Hallam conducted his post-doctoral training at the University of Cambridge and received his Ph.D. in biochemistry from King’s College, University of London.


Rodney Pearlman

Rodney Pearlman

Dr. Pearlman has over 30 years experience in scientific, strategic and leadership positions. His background includes Eli Lilly, the University of Texas, Genentech, Valentis, Saegis Pharmaceuticals, Nuan Therapeutics, RPM Pharma, InCardia Therapeutics and is currently president of The Bluefield Project. Dr. Pearlman received his M.S. and Ph.D. in pharmaceutical chemistry from The University of Kansas and has a B. Pharm from the Victorian College of Pharmacy in Melbourne, Australia.


Paul J. (PJ) Utz, MD

Paul J. (PJ) Utz, MD

Dr. Utz has over 20 years experience in the practice, research and instruction of medicine. His experience includes numerous scientific advisory boards, the Dana Farber Cancer Institute, Harvard Medical School and numerous positions at the Stanford University School of Medicine. Dr. Utz received his M.D. from the Stanford University School of Medicine and has a B.S. in Biology from King’s College, Wilkes-Barre, PA.


Michael C. Venuti, Ph.D.

Michael C. Venuti, Ph.D.

Dr. Venuti has over 30 years of experience in drug discovery and development.
His professional background includes Syntex, Genentech, Axys Pharmaceuticals, Celera, Discovery Partners International, BioSeek, iPierian and NeuroTherapeutics Pharma. Dr. Venuti conducted his post-doctoral training at the Institute of Organic Chemistry, Syntex Research, received his Ph.D. in synthetic organic chemistry from The Massachusetts Institute of Technology and has an A.B. in chemistry from Dartmouth College.

About

Our firm is focused on bringing extensive operating, financial and investment experience to the execution of transactions for life sciences companies.
[LEARN MORE]

Keep Up With Us



© 2014 Four Oaks Parnters. All rights reserved. Securities offered through Arque Capital, Ltd., Member FINRA/SIPC. Arque Capital Ltd., and Four Oaks Partners are unaffiliated entities.